We have also divided all the included patients into 4 disease subgroups (MPM, Lung cancer, Other malignancy and Others) and assessed SMRP levels and CYFRA 21-1/CEA ratio in each subgroup of patients using the complete-case dataset (Fig 2, Fig 3). This evidence concerns the gene MSLN and lung carcinoma.